New combo therapy aims to shrink sinus tumors before surgery
NCT ID NCT07645846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new approach for people with advanced sinonasal cancer (a rare cancer of the nasal cavity and sinuses). Before surgery, patients receive standard chemotherapy (docetaxel and cisplatin) plus two immunotherapy drugs (sintilimab and ipilimumab). The goal is to shrink the tumor enough to allow a less disfiguring surgery and improve long-term survival. The study will enroll 23 adults aged 18–75 who are healthy enough for aggressive treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- docetaxel, cisplatin, sintilimab, and ipilimumab
- What this could lead to
- If successful, this combination could shrink tumors enough to allow less extensive surgery, potentially preserving facial structures and improving survival for people with advanced sinonasal cancer.
- What could go wrong
- This is a small, early-phase trial with only 23 participants and no comparison group. The added immunotherapy may cause serious immune-related side effects, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SINONASAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.